Improving the biodistribution of PSMA‐targeting tracers with a highly negatively charged linker
BACKGROUND Prostate specific membrane antigen (PSMA) is overexpressed in prostate
cancer and in tumor vasculature. Small molecule based inhibitors of PSMA have promised …
cancer and in tumor vasculature. Small molecule based inhibitors of PSMA have promised …
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen–targeted imaging agent for prostate cancer
SE Lapi, H Wahnishe, D Pham, LY Wu… - Journal of Nuclear …, 2009 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found
on the surface of late-stage and metastatic prostate cancer and a well-known imaging …
on the surface of late-stage and metastatic prostate cancer and a well-known imaging …
[HTML][HTML] Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent
KLS Chatalic, S Heskamp, M Konijnenberg… - Theranostics, 2016 - ncbi.nlm.nih.gov
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging
and therapy of prostate cancer (PCa). Radiolabeled small-molecule PSMA inhibitors are …
and therapy of prostate cancer (PCa). Radiolabeled small-molecule PSMA inhibitors are …
Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer
E Murce, S Beekman, E Spaan, M Handula… - Molecules, 2023 - mdpi.com
Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been
successfully used for diagnosis and therapy of prostate cancer. Optimization of the available …
successfully used for diagnosis and therapy of prostate cancer. Optimization of the available …
[HTML][HTML] 177Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing …
CJ Choy, X Ling, JJ Geruntho, SK Beyer, JD Latoche… - Theranostics, 2017 - ncbi.nlm.nih.gov
Prostate-specific membrane antigen (PSMA) continues to be an active biomarker for small-
molecule PSMA-targeted imaging and therapeutic agents for prostate cancer and various …
molecule PSMA-targeted imaging and therapeutic agents for prostate cancer and various …
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand
SA Kularatne, K Wang, HKR Santhapuram… - Molecular …, 2009 - ACS Publications
Prostate cancer (PCa) is a major cause of mortality and morbidity in Western society today.
Current methods for detecting PCa are limited, leaving most early malignancies …
Current methods for detecting PCa are limited, leaving most early malignancies …
Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms
RAS Fragomeni, T Amir, S Sheikhbahaei… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is
highly overexpressed on prostate cancer epithelial cells and for which there is a growing …
highly overexpressed on prostate cancer epithelial cells and for which there is a growing …
Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer
Purpose: Prostate-specific membrane antigen (PSMA) is a cell surface protein that is
overexpressed in prostate cancer, including hormone-refractory and metastatic disease. Our …
overexpressed in prostate cancer, including hormone-refractory and metastatic disease. Our …
PSMA‐targeted SPECT agents: Mode of binding effect on in vitro performance
JR Nedrow‐Byers, AL Moore, T Ganguly… - The …, 2013 - Wiley Online Library
BACKGROUND The enzyme‐biomarker prostate‐specific membrane antigen (PSMA) is an
active target for imaging and therapeutic applications for prostate cancer. The internalization …
active target for imaging and therapeutic applications for prostate cancer. The internalization …
[HTML][HTML] Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
FC Gaertner, K Halabi, H Ahmadzadehfar, S Kürpig… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for
prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We …
prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We …